Special Issue "Cancer Diagnosis and Targeted Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 January 2011).
2. Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
Interests: interface between signal transduction and cancer with a focus on the alternative NF-kappaB signaling pathway, how it is regulated, and its contributions towards tumor development and resistance to conventional cancer therapies
Special Issues and Collections in MDPI journals
Special Issue in Biomedicines: Roles of NF-κB in Cancer and Their Therapeutic Approaches 2019
Topical Collection in Biomedicines: Targeting Cell Metabolism as Cancer Therapy
Special Issue in Biomedicines: Roles of NF-κB in Cancer and Their Therapeutic Approaches 2.0
Special Issue in Biomedicines: Feature Papers in Cancer Biology and Therapeutics
Special Issue in Biomedicines: Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)
Although mortality rates have declined in recent years, the majority of cancers are still difficult to treat and the medical need for better cancer treatment is evident. The current anticancer armamentarium includes many active agents that are applied across tumor types, and most drugs have a small therapeutic index and barely discriminate between malignant and normal cells. In recent years the focus has shifted to the development of rationally designed, molecularly-targeted therapy for the treatment of a specific cancer, therefore offering the promise of greater specificity coupled with reduced systemic toxicity. Another challenge has been the development of prognostic and pharmacogenomic biomarkers that enable the targeting of individualized treatments to those patients most likely to benefit.
This special issue will explore the routes from cancer research and oncogenomics into the development of novel mechanism-based cancer therapeutics and biomarkers.
We invite research and review papers in any area of oncology that are related, but not limited to, fundamental understanding of oncogenomics and cancer signaling pathways, diagnostic, prognostic and pharmacogenomic biomarkers, molecular diagnosis by gene expression profiling, molecular targets driving the progression of human cancers, cancer drug development on these targets, clinical trial with new agents, validation in animal models.
Dr. Veronique Baud
- cancer targeted diagnosis
- cancer targeted therapeutics
- solid tumors
- hematological malignancies
- gene expression profiling
- molecular targets
- mechanism-based drug development
- ubiquitin-proteasome pathway
- clinical trials
- animal models